Lanreotide

Description

Lanreotide is a synthetic octapeptide analogue of somatostatin with enhanced metabolic stability compared with somatostatin. It binds with high affinity to and stimulates the somatostatin receptors SSTR2 and SSTR5, with relatively greater potency at SSTR2 and very low binding to SSTR1, SSTR3 and SSTR4. It is used to treat acromegaly and neuroendocrine tumors.

Chemical Properties

White to off-white lyophilised powder

Uses

Antineoplas tic.

Side effects

Lanreotide depot was generally well tolerated, as 88% of patients had adverse events, compared with the placebo at 90%. Most adverse events were mild (17%) or moderate (44%) in both lanreotide and placebo groups. The most common adverse event was diarrhea at 26% in the lanreotide group and 9% with placebo. Abdominal pain was recorded in 14% of patients taking lanreotide but only occurred in 2% of patients taking placebo. Cholelithiasis occurred in 10% of patients but only 3% in the placebo group. Hyperglycemia occurred in 5% of lanreotide patients but was not observed in placebo patients.